{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:49:08Z","timestamp":1785008948843,"version":"3.55.0"},"reference-count":25,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gain-of-function gene alterations in rearranged during transfection (RET), a receptor tyrosine kinase, are observed in both sporadic and hereditary medullary thyroid cancers (MTCs) and pheochromocytomas and paragangliomas (PPGLs). Several tyrosine kinase inhibitors (TKIs) that target RET have been proven to be effective on MTCs and PCCs. Recently, TKIs, namely, sunitinib and selpercatinib, which were clinically used to target PPGLs, have been reported to decrease catecholamine levels without reducing tumor size. Our clinical case of metastatic medullary thyroid cancer, which is associated with RET mutations undergoing treatment with vandetanib, also suggests that vandetanib can decrease catecholamine levels. Therefore, we investigated the effect of vandetanib, a representative multi-targeted TKI for RET-related MTC, on cell proliferation and catecholamine synthesis in rat pheochromocytoma PC12 cells. Vandetanib reduced viable cells in a concentration-dependent manner. The dopamine and noradrenaline levels of the cell lysate were reduced in a concentration-dependent manner. They also decreased more prominently at lower concentrations of vandetanib compared to the inhibition of cell proliferation. The RNA knockdown study of Ret revealed that this inhibitory effect on catecholamine synthesis is mainly mediated by the suppression of RET signaling. Next, we focused on two signaling pathways downstream of RET, namely, ERK and AKT signaling. Treatment with vandetanib reduced both ERK and AKT phosphorylation in PC12 cells. Moreover, both an MEK inhibitor U0126 and a PI3K\/AKT inhibitor LY294002 suppressed catecholamine synthesis without decreasing viable cells. This study in rat pheochromocytoma PC12 cells reveals the direct inhibitory effects of vandetanib on catecholamine synthesis via the suppression of RET-ERK and RET-AKT signaling.<\/jats:p>","DOI":"10.3390\/ijms26146927","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T14:38:36Z","timestamp":1752849516000},"page":"6927","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhibitory Effects of Vandetanib on Catecholamine Synthesis in Rat Pheochromocytoma PC12 Cells"],"prefix":"10.3390","volume":"26","author":[{"given":"Yoshihiko","family":"Itoh","sequence":"first","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-2447","authenticated-orcid":false,"given":"Tomohiro","family":"Terasaka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisaku","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitomo","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-5170","authenticated-orcid":false,"given":"Jun","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: Expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1242\/dev.119.4.1005","article-title":"Expression of the c-ret proto-oncogene during mouse embryogenesis","volume":"119","author":"Pachnis","year":"1993","journal-title":"Development"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: Signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mce.2013.07.032","article-title":"Familial pheochromocytomas and paragangliomas","volume":"386","author":"King","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Romei, C., and Elisei, R. (2012). RET\/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front. Endocrinol., 3.","DOI":"10.3389\/fendo.2012.00054"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33577","DOI":"10.1074\/jbc.M605604200","article-title":"Structure and chemical inhibition of the RET tyrosine kinase domain","volume":"281","author":"Knowles","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728222.2013.758715","article-title":"RET inhibition: Implications in cancer therapy","volume":"17","author":"Borrello","year":"2013","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: From genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/jso.25869","article-title":"Screening guidelines and recommendations for patients at high risk of developing endocrine cancers","volume":"121","author":"Geurts","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E1813","DOI":"10.1210\/jc.2013-1653","article-title":"The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2","volume":"98","author":"Thosani","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: Results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): A single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1210\/clinem\/dgae283","article-title":"Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma","volume":"110","author":"Konda","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Chougnet","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","unstructured":"(2025, July 12). Available online: https:\/\/jglobal.jst.go.jp\/detail?JGLOBAL_ID=201802226714209958."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized Management of Pheochromocytoma and Paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/ERC-09-0292","article-title":"The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells","volume":"18","author":"Vitagliano","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1073\/pnas.0802785105","article-title":"Activation of PI3K\/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1","volume":"105","author":"Zhu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12022-012-9199-6","article-title":"Signaling pathways in pheochromocytomas and paragangliomas: Prospects for future therapies","volume":"23","author":"Grossman","year":"2012","journal-title":"Endocr. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/PO.21.00127","article-title":"Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma","volume":"5","author":"Mweempwa","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"bvac121","DOI":"10.1210\/jendso\/bvac121","article-title":"Effects of Wnt-beta-Catenin Signaling and Sclerostin on the Phenotypes of Rat Pheochromocytoma PC12 Cells","volume":"6","author":"Morimoto","year":"2022","journal-title":"J. Endocr. Soc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6927\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:22Z","timestamp":1760033542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":25,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146927"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146927","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}